Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Researchers from Wayne State University in Michigan are to conduct a series of preclinical and in-vitro experiments on Chemokine Therapeutics lead anticancer compound CTCE-9908.
Subscribe to our email newsletter
The studies will evaluate the ability of CTCE-9908 to inhibit the signaling and function of the CXCR4 receptor found on prostate cancer cells.
The CXCR4 receptor, present on many common cancers, has been observed to contribute to invasion of distant sites from the primary tumor, a process known as metastasis. Leading cancer researchers have demonstrated that high CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis rate and low survival rate.
The CXCR4 receptor is present on human prostate cancers cells as well as most other tumors, including lung, breast, colon, ovarian, bone, brain, and skin cancer.
CTCE-9908 targets the CXCR4 receptor and is part of a new generation of anticancer drug candidates that have the potential to both stop the spread of cancer and slow the rate of cancer growth.
The company recently announced a finding by Anti Cancer Inc that demonstrated CTCE-9908 prevented prostate cancer metastasis by over 60% in an animal model. Whilst a recent phase I, dose-escalation clinical trial using CTCE-9908 to assess safety in healthy volunteers demonstrated CTCE-9908 was safe and well tolerated by the study subjects after a single dose. Further clinical trials using CTCE-9908 are being planned by the company.